February 27, 2017
Recommended Topic Related To:

Subsys

"Nov. 29, 2012 (Chicago) -- For cancer patients undergoing chemotherapy who have found their complaints of general mental fogginess and haziness dismissed by their doctors as not being a real medical condition, vindication has arrived.

"...

A A A

Subsys

Indications
Dosage
How Supplied

INDICATIONS

SUBSYS is indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.

Patients considered opioid tolerant are those who are taking for one week or longer, around-the-clock medicine consisting of at least 60 mg of oral morphine per day, at least 25 mcg of transdermal fentanyl per hour, at least 30 mg of oral oxycodone per day, at least 8 mg of oral hydromorphone per day, or at least 25 mg oral oxymorphone per day, or at least 60mg oral hydrocodone per day, or an equianalgesic dose of another opioid daily for a week or longer. Patients must remain on around-the-clock opioids when taking SUBSYS.

Limitations Of Use

  • Not for use in opioid non-tolerant patients.
  • Not for use in the management of acute or postoperative pain, including headache/migraine, dental pain, or in the emergency room [see CONTRAINDICATIONS].
  • As part of the Transmucosal Immediate-Release Fentanyl (TIRF) REMS ACCESS Program, SUBSYS may be dispensed only to outpatients enrolled in the program. [see WARNINGS AND PRECAUTIONS]. For inpatient administration (e.g. hospitals, hospices, and long-term care facilities that prescribe for inpatient use) of SUBSYS, patient enrollment is not required.

DOSAGE AND ADMINISTRATION

Important Dosage And Administration Instructions

  • Healthcare professionals who prescribe SUBSYS on an outpatient basis must enroll in the TIRF REMS ACCESS program and comply with the requirements of the REMS to ensure safe use of SUBSYS. [see WARNINGS AND PRECAUTIONS]
  • Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals [see WARNINGS AND PRECAUTIONS].
  • It is important to minimize the number of strengths available to patients at any time to prevent confusion and possible overdose.
  • Initiate the dosing regimen for each patient individually, taking into account the patient's severity of pain, patient response, prior analgesic treatment experience, and risk factors for addiction, abuse, and misuse [see WARNINGS AND PRECAUTIONS].
  • Monitor patients closely for respiratory depression, especially within the first 24-72 hours of initiating therapy and following dosage increases with SUBSYS and adjust the dosage accordingly [see WARNINGS AND PRECAUTIONS].
  • Instruct patients and caregivers to take steps to store SUBSYS securely and to properly dispose of unused SUBSYS as soon as no longer needed [see WARNINGS AND PRECAUTIONS, PATIENT INFORMATION].
  • Other TIRF formulations and SUBSYS are not equivalent. DO NOT substitute a SUBSYS prescription for any other TIRF formulation under any circumstances. Do not convert patients on a mcg per mcg basis from any other fentanyl product to SUBSYS [see WARNINGS AND PRECAUTIONS]
  • SUBSYS is not bioequivalent with other fentanyl products. Do not convert patients on a mcg per mcg basis from other fentanyl products. There are no conversion directions available for patients on any other fentanyl products, other than Actiq. (Note: This includes oral, transdermal, or parenteral formulations of fentanyl.) [see WARNINGS AND PRECAUTIONS].
  • SUBSYS is NOT a generic version of any other oral transmucosal fentanyl product [see WARNINGS AND PRECAUTIONS].

Initial Dosage

Initiate treatment with SUBSYS for all patients (including those switching from another fentanyl product) using ONE 100 mcg spray sublingually.

Prescribe an initial titration supply of 100 mcg SUBSYS units, which limits the number of units in the home during titration.

Avoid prescribing a higher dose until patients have used up all units to prevent confusion and possible overdose.

Conversion From Actiq To SUBSYS

The initial dose of SUBSYS is always 100 mcg with the only exception of patients already using Actiq.

  1. For patients being converted from Actiq, prescribers must use the Initial Dosing Recommendations for Patients on Actiq table below (Table 1). Patients must be instructed to stop the use of Actiq and dispose of any remaining units.
  2. Table 1: Initial Dosing Recommendations for Patients on ACTIQ

    Current ACTIQ Dose (mcg) Initial SUBSYS Dose (mcg)
    200 100 mcg spray
    400 100 mcg spray
    600 200 mcg spray
    800 200 mcg spray
    1200 400 mcg spray
    1600 400 mcg spray

  3. For patients converting from Actiq doses 400 mcg and below, titration should be initiated with 100 mcg SUBSYS and should proceed using multiples of this strength.
  4. For patients converting from Actiq doses of 600 and 800 mcg, titration should be initiated with 200 mcg SUBSYS and should proceed using multiples of this strength.
  5. For patients converting from Actiq doses of 1200 and 1600 mcg, titration should be initiated with 400 mcg SUBSYS and should proceed using multiples of this strength.

Dosage Modifications In Patients With Oral Mucositis

In cancer patients with mucositis, exposure to SUBSYS was greater than in patients without mucositis. For patients with Grade 1 mucositis, the increased maximum serum concentration and overall exposure requires closer monitoring for respiratory depression and central nervous system depression, particularly during initiation of therapy with SUBSYS. For patients with Grade 2 mucositis or higher, avoid use of SUBSYS unless the benefits outweigh the potential risk of respiratory depression from increased exposure. [see CLINICAL PHARMACOLOGY]

Titration And Maintenance Of Therapy

Individually titrate SUBSYS to a dose that provides adequate analgesia and minimizes adverse reactions.

  1. From the 100 mcg initial dose, closely follow patients and change the dosage level until the patient reaches a dose that provides adequate analgesia using a single SUBSYS dose per breakthrough cancer pain episode with tolerable side effects. Patients should record their use of SUBSYS over several episodes of breakthrough cancer pain and review their experience with their physicians to determine if a dosage adjustment is warranted.
  2. For each breakthrough pain episode treated, if pain is not relieved after 30 minutes, patients may take ONLY ONE additional dose of the same strength for that episode. Thus patients should take a maximum of two doses of SUBSYS for any breakthrough pain episode.
  3. Patients MUST wait at least 4 hours before treating another episode of breakthrough pain with SUBSYS.
  4. If there is a need to titrate to a 200 mcg dose, prescribe 200 mcg SUBSYS units.
  5. Subsequent titration steps are 400 mcg, 600 mcg, 800 mcg, 1200 mcg and 1600 mcg. See Table 2.
  6. To reduce the risk of overdose during titration, patients should have only one strength of SUBSYS available at any time.

Table 2: Titration Steps

SUBSYS DOSE Using
100 mcg 1 x 100 mcg unit
200 mcg 1 x 200 mcg unit
400 mcg 1 x 400 mcg unit
600 mcg 1 x 600 mcg unit
800 mcg 1 x 800 mcg unit
1200 mcg 2 x 600 mcg unit
1600 mcg 2 x 800 mcg unit

SUBSYS Titration Process

ingestion -  Illustration

Once titrated to a dose that provides adequate pain relief and tolerable side effects, patients should generally use ONLY ONE SUBSYS dose of the appropriate strength per breakthrough pain episode.

On those occasions when the breakthrough pain episode is not relieved within 30 minutes after administration of the SUBSYS dose, the patient may take ONLY ONE additional dose using the same strength for that episode.

Patients MUST wait at least 4 hours before treating another episode of breakthrough pain with SUBSYS. Once a successful dose has been found, patients should limit consumption to four or fewer doses per day.

Dosage adjustment of SUBSYS may be required in some patients in order to continue to provide adequate relief of breakthrough pain.

If signs of excessive opioid effects appear following administration of a single SUBSYS dose, subsequent doses should be decreased.

Generally, only increase the SUBSYS dose when a single administration of the current dose fails to adequately treat the breakthrough pain episode for several consecutive episodes.

If the patient experiences greater than four breakthrough pain episodes per day, the dose of the maintenance (around-the-clock) opioid used for persistent pain should be re-evaluated. In addition, if pain worsens, re-evaluate the patient for changes in the underlying pain condition.

Discontinuation Of SUBSYS

For patients no longer requiring opioid therapy, consider discontinuing SUBSYS along with a gradual downward titration of other opioids to minimize possible withdrawal effects. In patients who continue to take their chronic opioid therapy for persistent pain but no longer require treatment for breakthrough pain, SUBSYS therapy can usually be discontinued immediately. [see Drug Abuse and Dependence].

Disposal Of SUBSYS

Patients and caregivers must be advised to dispose of used unit dose systems immediately after use and any unneeded unit dose systems remaining from a prescription as soon as they are no longer needed. Consumed units represent a special risk because they are no longer protected by the child resistant blister package, yet may contain enough medicine to be fatal to a child. [see PATIENT INFORMATION].

Charcoal-lined disposal pouches are provided with every carton dispensed. A charcoal-lined disposal pouch is to be used by patients or their caregivers to dispose of the contents of any unneeded unit dose systems when they are no longer needed. Instructions for usage of the charcoal-lined disposal pouch are included in the Medication Guide and Instructions for Use.

HOW SUPPLIED

Dosage Forms And Strengths

SUBSYS is a sublingual spray available in 100 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1200 mcg, and 1800 mcg strengths. SUBSYS is supplied as spray units consisting of a white actuator attached to a light purple vial holder [see HOW SUPPLIED/Storage and Handling]. 100 mcg, 200 mcg, 400 mcg, 600 mcg, and 800 mcg doses are delivered as a single unit (spray). To administer 1200 mcg and 1800 mcg doses, two units (sprays) must be used.

Each dosage strength is differentiated by the color of the blister package, and carton as described below in Table 3. The strength of the spray unit is indicated on the actuator.

Table 3: Subsys Strengths

Dosage Strength (fentanyl base) Using Carton/Blister Package Color
100 mcg 1 x 100 mcg unit packaged in a single blister Blue
200 mcg 1 x 200 mcg unit packaged in a single blister Green
400 mcg 1 x 400 mcg unit packaged in a single blister Magenta (Pink)
600 mcg 1 x 600 mcg unit packaged in a single blister Purple
800 mcg 1 x 800 mcg unit packaged in a single blister Orange
1200 mcg 2 x 600 mcg units packaged in a single blister Brown
1600 mcg 2 x 800 mcg units packaged in a single blister Red

SUBSYS (fentanyl sublingual spray) is supplied as spray units.

Each SUBSYS carton contains individual blister packages containing spray units of SUBSYS, a supply of small white disposal bags for disposing of used SUBSYS units and charcoal-lined disposal pouches, a supply of charcoal-lined disposal pouches (wrapped in aluminum foil) for use when disposing of the contents of unused SUBSYS units, a Medication Guide and a Package Insert.

SUBSYS is supplied in individually sealed, protective blister packages. These blister packages are packed into 10 and 30 per shelf cartons.

Each unit dose system consists of a white actuator attached to a light purple vial holder. The dosage strength is marked on the label on the actuator, the blister package and the shelf carton. See the protective blister package and shelf carton for product information.

Dosage Strength (fentanyl base) Carton/Blister Package Color NDC Number
100 mcg Blue 20482-001-10
20482-001-30
200 mcg Green 20482-002-10
20482-002-30
400 mcg Magenta (Pink) 20482-004-10
20482-004-30
600 mcg Purple 20482-006-10
20482-006-30
800 mcg Orange 20482-008-10
20482-008-30
1200 mcg Brown 20482-012-15
1600 mcg Red 20482-016-15

Note: Colors are a secondary aid in product identification. Please be sure to confirm the printed dosage before dispensing.

Storage And Handling

Store at 20-25°C (68-77°F) with excursions permitted between 15° and 30°C (59° to 86°F) until ready to use. [See USP Controlled Room Temperature.] Do not use if the blister package has been opened.

DPT Laboratories, Ltd., Lakewood, NJ 08701. Manufactured for and Distributed by: Insys Therapeutics, Inc. 1333 South Spectrum Blvd, Suite 100 Chandler, AZ 85286. Revised: Dec 2016

This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 1/6/2017

Indications
Dosage
How Supplied

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Cancer

Get the latest treatment options.